COG grant:  $30-$60,000 per year depending on protocol accrual; R. Parker P.I.

Parker RI, Mahan RM, Giugliano DA: Delayed methotrexate clearance during treatment with amphotericin B. Journal of Pediatric Hematology/Oncology 24:A20, 1452, 2002.

Metha P, Parker RI, Galvin-Parton P, Wilson TA, Prakash D:  Imbalance of plasminogen activator inhibitor type-1 (PAI-1) and tissue-plasminogen activator (t-PA) activity in patients with Noonan syndrome.  (Accepted for presentation at the American Society of Pediatric Hematology/Oncology - Pediatric Academic Societies Annual meeting, Baltimore, MD, May 2002).  Journal of Pediatric Hematology/Oncology 24:A29, 1498, 2002.

Maloney JM, Whelan MA, Parker RI, Mueller L, Prakash D: Effect of chemotherapy on T-cell populations and the maintenance of immunity to vaccinations.  (Accepted for presentation at the American Society of Pediatric Hematology/Oncology - Pediatric Academic Societies Annual meeting, Seattle, WA, May 2003) Journal of Pediatric Hematology/Oncology 25:A25, 1655, 2003.

Aleyas M, Hogan L, Parker RI:  Osteopenia in survivors of childhood lymphoid malignancy.  (Accepted for presentation at the American Society of Pediatric Hematology/Oncology – Pediatric Academic Societies Annual meeting, Washington D.C., May 2005) Pediatr Blood Cancer 44:1166, 564, 2005.

Parker RI, Prakash D, Giugliano D, Mahan RA, Atlas M:  A randomized double-blind cross-over placebo-controlled trial of intravenous ondansetron for the prevention of post-intrathecal chemotherapy induced vomiting in children.  J Ped Hematol/Oncol 23:578-581, 2001.

Ancona K, Parker RI, Atlas M, Prakash D:  A randomized trial of high dose methylprednisolone vs. IV-IgG for the treatment of acute ITP in children.  J Pediatr Hematol/Oncol 24:540-544, 2002.

Parker, RI:  IIb/IIIa or not IIb/IIIa, that is adhesion. (editorial)  Crit Care Med 29:1286-87, 2001.

Parker RI:  Hypercoagulable States, in: Saunders Manual of Critical Care, Kruse JA, Fink MP, Carlson RW, eds., pp6413-415, Saunders Publishing, Philadelphia, PA, 2002.

Parker RI: Thrombolytic Agents, in: Saunders Manual of Critical Care, Kruse JA, Fink MP, Carlson RW, eds., pp622-623, Saunders Publishing, Philadelphia, PA, 2002.

Parker RI: DIC in Children, in:  UpToDate, UpToDate publishers web-based text – 2003.

Parker RI:  Thrombocytopenia and ICU outcome: A sticky issue. (editorial) Crit Care Med 30:1917-1918, 2002.

Parker RI:  Low Molecular Weight Heparins – Are they all the Same?  Criticare 2004: Proceedings of the 10th Annual Conference of ISCCM, Mumbai, India, Karnad DR, ed, pp97-100, 2004.

Parker RI:  Heparin Induced Thrombocytopenia:  Essential Elements for the Clinician.  J Respir Dis 25:103-112, 2004.

Parker RI:  Hematologic Issues in the PICU. Critical Connections 3:16, 2004.

Parker RI: Abnormalities of Coagulation, thrombosis and platelets, in:  Intensive Care of the Fetus and Newborn, 2nd edition, Spitzer AR, editor., pp. 1295-1312,  Elsevier Mosby, Inc, Philadelphia, PA, 2005.

Parker RI:  Heparin Induced Thrombocytopenia:  Essential Elements for the Clinician.  J Crit Ill 20:64-71, 2005.

Parker, RI:  Recombinant F.VIIa:  Panacea or Passing Fad. (editorial)  Crit Care Med 6:379-80, 2005.

Parker RI:  Factor V Leiden and Sepsis:  Proof Positive or Phenomenology? (editorial)  Crit Care Med 2006 – in press.

Parker RI, Mahan RM, Giugliano DA and Whyte D:  Delayed Methotrexate Clearance in the presence of Amphotericin-B (submitted).

Metha P, Prakash D, Galvin-Parton P, Wilson TA, Parker RI:  Imbalance of plasminogen activator inhibitor type-1 (PAI-1) and tissue-plasminogen activator (t-PA) activity in patients with Noonan syndrome.  (submitted)